Lars Fruergaard Jorgensen
Lars Fruergaard Jorgensen is the CEO of Novo Nordisk, a Danish pharmaceutical company renowned for its innovative treatments for diabetes and obesity. Under his leadership, the company has focused on expanding its portfolio of obesity medications, including the highly successful Wegovy. Jorgensen has emphasized the strong demand for obesity treatments, despite market fluctuations and competition from other pharmaceutical companies.
Not in the pool (under ¢1).
Recent news mentions
Lars Fruergaard Jörgensen, the CEO of Novo Nordisk, commented on the fears of food companies regarding the impact of obesity medications.
wie die Abnehmspritze die Lebensmittelindustrie verändert
Switzerland· 2025-11-14
Lars Fruergaard Jörgensen was the long-time CEO of Novo Nordisk before being dismissed.
Wie Trump den Pharmariesen trifftSwitzerland· 2025-08-25
Lars Fruergaard Jorgensen, Novo’s former Chief Executive Officer, was called to testify about the pricing of his company’s drugs.
Ozempic maker Novo Nordisk cuts price of wonder drug in half
Australia· 2025-08-18
Lars Fruergaard Jorgensen is the CEO of Novo Nordisk.
Bráð brisbólga algeng aukaverkun þyngdarstjórnunarlyfja
Iceland· 2025-06-27
Lars Fruergaard Jorgensen was the CEO of Novo Nordisk who was ousted over concerns about the company's market position.
Novo Nordisk launches weight-loss drug Wegovy in India to compete with Lilly’s Mounjaro - World
Pakistan· 2025-06-24
Lars Fruergaard Jörgensen led Novo Nordisk to success but was unexpectedly dismissed in May.
Vom Aufstieg mit Ozempic zum BörsenabsturzSwitzerland· 2025-06-13
Lars Fruergaard Jorgensen was forced out as chief executive of Novo Nordisk.
What big Canadian retailer got sold this week? Take our business and investing news quiz for the week ending May 23
Canada· 2025-05-26
Lars Fruergaard Jorgensen will leave his position as CEO of Novo Nordisk after the company's stock fell over 50% in the last 12 months.
Novo Nordisk, il ceo si dimette dopo il crollo in Borsa: -50% in 12 mesi (due anni fa era la regina d’Europa)
Italy· 2025-05-16Lars Fruergaard Jorgensen is stepping down as CEO of Novo Nordisk due to recent market challenges.
Lars Fruergaard Jorgensen, CEO of Novo Nordisk, which makes Wegovy, is stepping down
United States· 2025-05-16Lars Fruergaard Jörgensen was the CEO of Novo Nordisk and is stepping down after eight years due to market challenges.
CEO der Pharmagruppe Novo Nordisk tritt zurückSwitzerland· 2025-05-16Novo Nordisk CEO Lars Fruergaard Jorgensen said on a call with journalists that growth is expected to pick up in the second-half of the year.
Market movers: Stocks that saw action on Wednesday - and whyCanada· 2025-05-08
Lars Fruergaard Jorgensen is the CEO of Novo who mentioned that his company would feel the short-term effects of tariffs.
Bodo carine zvišale cene zdravil ali pa se bodo farmacevti iz EU preselili v ZDA
Slovenia· 2025-03-18
Lars Fruergaard Jorgensen is the CEO of the Danish company Novo Nordisk.
Novo Nordisk отчита двоен ръст на продажбите на лекарството за отслабване Wegovy
Bulgaria· 2025-02-24
Lars Fruergaard Jorgensen is the CEO of Novo Nordisk and commented on the strong demand for obesity treatment drugs.
Novo Nordisk отчита двоен ръст на продажбите на лекарството за отслабване WegovyBulgaria· 2025-02-24